These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15816106)

  • 1. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.
    Eriksen JG; Steiniche T; Overgaard J;
    Radiother Oncol; 2005 Feb; 74(2):93-100. PubMed ID: 15816106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
    Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
    J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.
    Eriksen JG; Steiniche T; Askaa J; Alsner J; Overgaard J
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):561-6. PubMed ID: 14751528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.
    Nijkamp MM; Span PN; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende PL; de Jong M; van der Kogel AJ; Bussink J; Kaanders JH
    Eur J Cancer; 2013 Oct; 49(15):3202-9. PubMed ID: 23867129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.
    Eriksen JG; Steiniche T; Overgaard J;
    Acta Oncol; 2005; 44(1):50-8. PubMed ID: 15848906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.
    Buffa FM; Bentzen SM; Daley FM; Dische S; Saunders MI; Richman PI; Wilson GD
    Clin Cancer Res; 2004 Jun; 10(11):3745-54. PubMed ID: 15173081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.
    Pedicini P; Nappi A; Strigari L; Jereczek-Fossa BA; Alterio D; Cremonesi M; Botta F; Vischioni B; Caivano R; Fiorentino A; Improta G; Storto G; Benassi M; Orecchia R; Salvatore M
    Radiat Oncol; 2012 Aug; 7():143. PubMed ID: 22920680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DAHANCA 6 randomized trial: Effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma.
    Lyhne NM; Primdahl H; Kristensen CA; Andersen E; Johansen J; Andersen LJ; Evensen J; Mortensen HR; Overgaard J
    Radiother Oncol; 2015 Oct; 117(1):91-8. PubMed ID: 26255764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times.
    Eriksen JG; Alsner J; Steiniche T; Overgaard J
    Radiother Oncol; 2005 Aug; 76(2):135-42. PubMed ID: 16024113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck.
    Watson RF; Chernock RD; Zhang KH; Michel LS; Adkins DR; El-Mofty SK; Lewis JS
    Head Neck Pathol; 2015 Sep; 9(3):360-8. PubMed ID: 25563452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
    Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
    Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy.
    Slavik M; Shatokhina T; Sana J; Ahmad P; Kazda T; Selingerova I; Hermanova M; Cervena R; Novotny T; Burkon P; Smilek P; Horakova Z; Slampa P; Slaby O
    Head Neck; 2019 Apr; 41(4):940-949. PubMed ID: 30552846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
    Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
    J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial.
    Suwinski R; Jaworska M; Nikiel B; Grzegorz W; Bankowska-Wozniak M; Wojciech M; Krzysztof S; Dariusz L
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):438-46. PubMed ID: 19733016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.
    Overgaard J; Mohanti BK; Begum N; Ali R; Agarwal JP; Kuddu M; Bhasker S; Tatsuzaki H; Grau C
    Lancet Oncol; 2010 Jun; 11(6):553-60. PubMed ID: 20382075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer.
    Pattje WJ; Schuuring E; Mastik MF; Slagter-Menkema L; Schrijvers ML; Alessi S; van der Laan BF; Roodenburg JL; Langendijk JA; van der Wal JE
    Br J Cancer; 2010 Jun; 102(12):1778-85. PubMed ID: 20502457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.
    Szabó B; Nelhubel GA; Kárpáti A; Kenessey I; Jóri B; Székely C; Peták I; Lotz G; Hegedus Z; Hegedus B; Füle T; Döme B; Tímár J; Tóvári J
    Oral Oncol; 2011 Jun; 47(6):487-96. PubMed ID: 21498106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.